Compare InMode Ltd (INMD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Sanofi SA — how do they compare? InMode Ltd trades at $14.21 (market cap $809.93M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 117.5× InMode Ltd's market cap, and Sanofi SA pays a 6.01% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Sanofi SA for 94 Days on average.
| INMD | SNY | |
|---|---|---|
Market Cap | $809.93M | $95.18B |
Volume | 365,490 | 2,995,646 |
Sector | Health | Health |
52-Week High | $16.62 | $52.34 |
52-Week Low | $12.76 | $39.51 |
Typical Hold Time | 28 Days | 94 Days |
Enterprise Value | $313.27M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.21, up 1.43% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 11.63, gross margins of 76.52%, and consistent profitability. Recent Q2 2026 earnings beat expectations with $95.6M revenue, while facing shareholder activism from Steel Partners' $16.75 per share acquisition offer.
Investment outlook remains cautious with analyst consensus divided (45% Buy, 55% Hold) amid cyclical industry softness. Key opportunities include international growth and new product launches like Morpheus8 Cool, while risks involve US sales declines and capital allocation concerns. The stock presents value characteristics but requires monitoring of management's strategic response to acquisition pressure.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
